Grufity logo
Grufity logo
TLIS

TLIS - Talis Biomedical Corporation Stock Price, Fair Value and News

$2.84 
Market Closed as of 01 Apr 2026, 04:00 pm ET

Price Targets

TLIS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TLIS Price Action

Trailing 12 Months

63.2%

TLIS RSI Chart

TLIS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TLIS Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

5.23

Price/Free Cashflow

-0.13

TLIS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

TLIS Fundamentals

TLIS Revenue

TLIS Earnings

TLIS Profitability

Free Cashflow Yield

-777.5%

TLIS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2024989.0K---
20232.8M2.9M2.2M2.1M
20224.4M4.8M5.4M4.8M
202117.5M16.8M7.6M8.2M
2020---10.9M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Talis Biomedical Corporation

TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.
 CEO
 WEBSITEhttps://talisbio.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES102

Talis Biomedical Corporation Frequently Asked Questions

TLIS is the stock ticker symbol of Talis Biomedical Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Apr 01 2026, market cap of Talis Biomedical Corporation is 5.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Apr 01 2026, TLIS's PE ratio (Price to Earnings) is -0.1 and Price to Sales (PS) ratio is 5.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TLIS PE ratio will change depending on the future growth rate expectations of investors.